MIM
CADL icon

MetLife Investment Management’s Candel Therapeutics CADL Stock Holding History

MetLife Investment Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$79.4K Sell
16,199
-3,244
-17% -$17.7K ﹤0.01% 2622
2025
Q4 		$110K Buy
19,443
+3,955
+26% +$21.3K ﹤0.01% 2561
2025
Q3 		$79K Sell
15,488
-10,058
-39% -$58.1K ﹤0.01% 2736
2025
Q2 		$129K Buy
25,546
+10,319
+68% +$53.1K ﹤0.01% 2406
2025
Q1 		$86K Buy
15,227
+1,454
+11% +$11.9K ﹤0.01% 2592
2024
Q4 		$120K Buy
13,773
+1,215
+10% +$7.18K ﹤0.01% 2535
2024
Q3 		$87K Buy
+12,558
New +$78K ﹤0.01% 2679

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's CADL Position: Q1 2026 in Review

MetLife Investment Management reduced its Candel Therapeutics (CADL) stake by 17% in Q1 2026, selling an estimated $17.7K and leaving 16,199 shares worth $79.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2622.

MetLife Investment Management first reported a position in CADL in Q3 2024 and has held it in 7 quarters since. The position peaked at $129K in Q2 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • MetLife Investment Management held 16,199 shares of Candel Therapeutics worth $79.4K as of Q1 2026.
  • MetLife Investment Management sold 3,244 Candel Therapeutics shares in Q1 2026, an estimated $17.7K.
  • Candel Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2622 holding.
  • MetLife Investment Management first reported a position in Candel Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • MetLife Investment Management's Candel Therapeutics position peaked at $129K in Q2 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.